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Hypertension after kidney transplant is a frequent occurrence in pediatric patients. It
is a risk factor for graft loss and contributes to the significant burden of cardiovascular
disease (CVD) in this population. The etiology of posttransplant hypertension is multifactorial including donor factors, recipient factors, medications, and lifestyle factors similar
to those prevalent in the general population. Ambulatory blood pressure monitoring has
emerged as the most reliable method for measuring hypertension in pediatric transplant
recipients, and many consider it to be essential in the care of these patients. Recent
technological advances including measurement of carotid intima-media thickness, pulse
wave velocity, and myocardial strain using specked echocardiography and cardiac
magnetic resonance imaging have improved our ability to assess CVD burden. Since
hypertension remains underrecognized and inadequately treated, an early diagnosis and
an appropriate control should be the focus of therapy to help improve patient and graft
survival.
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INTRODUCTION
Hypertension after renal transplantation is a common phenomenon with an estimated prevalence
of 70–90% in adults and 58–89% in children (1–3). Long-standing hypertension has been associated with allograft dysfunction, premature atherosclerosis, and cardiomyopathy (4, 5).
Cardiovascular disease (CVD) is much more common among children with chronic kidney
disease (CKD) and end-stage renal disease (ESRD) compared to the general population. CVD
accounts for a large proportion of morbidity and mortality in this population (6). Renal transplantation improves CVD risk. Compared to patients awaiting transplantation, transplant recipients
experience a substantial reduction in the CVD-associated death rate, especially from adolescence
onward while they maintain good graft function (7–11). However, hypertension remains a significant and modifiable risk factor for CVD in pediatric transplant recipients. Studies have shown that
transplant patients have better systolic and diastolic function than those receiving hemodialysis or
peritoneal dialysis (PD), despite having increased prevalence of hypertension and left ventricular
hypertrophy (LVH) (12). In addition to offering transplantation to ameliorate the cardiovascular
effects of ESRD, aggressively treating blood pressure in transplant recipients would further reduce
the prevalence of CVD.
The etiology of posttransplant hypertension is multifactorial encompassing donor-associated
factors, side effects of immunosuppressive medications, underlying recipient disease, and possibly
genetic factors, as seen in Figure 1. The treatment strategies vary by timing after transplant as well
as the pathophysiological contributors to hypertension. This review will cover etiology of posttransplant hypertension, effects of hypertension on the patient, graft survival, assessment methods, and
treatment options.
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Recipient Factors

Recipient factors such as recurrence of original disease in the
graft and presence of native kidneys are known contributors to
posttransplant hypertension. Occasionally, native nephrectomies
are performed prior to or at the time of transplant to help with
management of hypertension (22). However, this is becoming an
uncommon practice because recent data suggest that the benefit
is limited (23).
Pediatric patients with pretransplant obesity have significantly
higher systolic blood pressure (SBP) and worse glomerular filtration rate (GFR) than children with normal body mass index
prior to transplant (24). The incidence of pretransplant obesity is
increasing mirroring the rise of obesity in the general pediatric
population (25). As in the general population, the development
of overweight or obesity after transplantation in children is
associated with hypertension and poor glycemic control (26, 27).
While these CVD risk factors can more pronounced due to the
known side effects of immunosuppressant medications, the effect
of obesity on hypertension in the pediatric transplant recipient
has been shown to be independent of posttransplant use of
steroids (28).
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Transplant
renal artery
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Recurrent
Disease
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Effects

Effects of Medications

Immunosuppressive medications play a significant role in the
development of posttransplant hypertension. It has been well
established that corticosteroids induce hypertension by increasing renal salt and water reabsorption and increase in renal
vascular resistance. Studies have shown that patients on steroidminimization protocols and patients undergoing late-withdrawal
of steroids showed reduction in hypertension and obesity and
improved lipid and carbohydrate metabolism (29).
The incidence of posttransplant hypertension significantly
increased after calcineurin inhibitors (CNI) such as cyclosporine
and tacrolimus became commercially available for use. A recent
Greek cohort of pediatric transplant patients showed that there
was an increased risk of hypertension for patients on a CNI-based
immunosuppression protocol (14).
The mechanism of CNI-induced hypertension is primarily
mediated by glomerular afferent arteriolar constriction leading
to increased salt and water retention, in part through upregulation of the thiazide-sensitive Na+-Cl− cotransporter (30, 31).
Additional mechanisms include activation of renin angiotensin
aldosterone system and secretion of reactive oxygen species
(32, 33). An imbalance between vasoconstrictive molecules
(endothelin, thromboxane, and prostaglandins) and vasodilatory
nitric oxide also contributes to the development of hypertension (34, 35). Finally, prolonged CNI exposure causes increased
production of transforming growth factor-β production, which
leads to fibrosis and long-term graft damage (36–38). Tacrolimus
has become the preferred CNI in clinical practice as it causes
less hypertension and hyperlipidemia, as well as improved graft
survival when compared to cyclosporine (39, 40).
Previously, it has been shown that mammalian target of rapamycin (mTOR) inhibitors act synergistically with CNI to worsen
hypertention (41). Brunkhorst et al. (2015) recently compared
the efficacy and safety of an everolimus and low-dose CSA regimen to standard dose cyclosporine and mycophenolate mofetil

FIGURE 1 | Etiology of posttransplant hypertension.

ETIOLOGY OF HYPERTENSION
Donor Factors

It has been well established that several independent donor
risk factors predispose the transplant recipient to hypertension
including deceased donor, older age, and donor hypertension
(13, 14). It is theorized that the increased risk comes from longer
cold ischemia time, damaged graft vessels from hypertension,
and age-related glomerular dropout in older donors. Due to these
reasons, most transplant centers do not accept donors beyond
a certain age or those with hypertension for pediatric recipients
except in extenuating circumstances. Extended criteria donor
kidneys have been associated with increased risk of death from
CVD in the adult population and usually are not accepted for
pediatric recipients (15).
The kidney donor profile index (KDPI) scoring system, used
to evaluate donor grafts, was recently introduced in the United
States (16). Donors with lower KDPI have potential for better
graft survival, and pediatric recipients get preference for donors
with lower KDPI scores, and most pediatric transplant centers
will not accept kidneys with high KDPI scores for children.
There are no data yet on long-term CVD outcomes for transplant
recipients based on donor KDPI scores.
Recently, donor genetic variants have been found to contribute to poor graft function and posttransplant hypertension.
Polymorphisms including apolipoprotein L1 (APOL1), ATPBinding Cassette Subfamily B Member 1 (ABCB1), Caveolin 1
(CAV1), and ATP-Binding Cassette Subfamily C Member 2
(ABCC2) have been shown to affect graft survival, hypertension,
and calcineurin-induced nephrotoxicity (17–21). Currently,
there is no standard for screening for these polymorphisms.
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therapy in 105 pediatric transplant patients. They found that the
everolimus group had comparable graft function and survival
but more dyslipidemia and arterial hypertension than the control
group (42). This suggests that mTOR inhibitors have an effect on
posttransplant hypertension independent of or in synergy with
the CNI effect, although the precise mechanism is not yet known.

30–50% recurrence risk in the first transplant and 80–100% in
subsequent transplants (48). Some transplant patients develop de
novo glomerular disorders after transplant that may include FSGS
and MGN. These glomerular disorders have the potential to cause
hypertension, and poor blood pressure control will accelerate
renal function decline (49–51).

Transplant Renal Artery Stenosis (TRAS)

Acute Rejection (AR)

Transplant renal artery stenosis is the most common vascular complication after renal transplant, usually presenting
2 months–2 years after transplant (43). Clinical signs are usually
worsening or refractory hypertension with or without graft dysfunction (44). It has a reported prevalence of 1–23% and accounts
for 1–5% of posttransplant hypertension (45).
Risk factors for TRAS include surgical technique, deceased
donor, cytomegalovirus infection, and prolonged ischemia time
(46). A recent study investigated the role of genetic polymorphisms in the myosin heavy chain 9 (MYH9) gene on TRAS. The
product of this gene is heavily expressed in glomeruli, tubular,
and renal capillaries as well as arteriolar endothelial cells. Donor
organs found to carry the rs3752462 CC variant had a 10.9-fold
increase in TRAS compared to the recipients carrying rs5756168
TT variant that had a 3.45-fold decrease in risk (47).

Acute rejection can be T-cell and antibody mediated and is
often associated with hypertension. Any transplant patient with
sudden onset or worsening of hypertension should be assessed
for AR. The hypertension in this case usually responds well to
treatment of AR.

Graft Dysfunction

While patients with ESRD have numerous additional risk
factors compared to normal children for developing hypertension, common risk factors for hypertension present in the
general population also prevail in kidney transplant recipients.
These risk factors include tobacco smoking, illicit drug use,
medications for attention deficit hyperactivity disorder,
high-salt diet, physical inactivity, obesity, sleep disturbances
including obstructive sleep apnea, and genetic determinants of
hypertension (55–59). Figure 2 outlines the common etiologies

Chronic Rejection, Also Known As Chronic
Transplant Glomerulopathy (TG)

Transplant glomerulopathy causes hypertension through progressive scarring and fibrosis. Recent data showed that non-HLA
autoantibodies targeting the angiotensin II type-1 receptor have
been linked to hypertension, and treatment with an angiotensin
receptor blocker may be beneficial (52–54).

Common Risk Factors Prevalent in
the General Population

Recurrent and De Novo Glomerular Diseases

Many underlying glomerular diseases in the recipient can recur
in the transplant allograft including focal segmental glomerulosclerosis (FSGS), atypical hemolytic uremic syndrome (aHUS),
antiglomerular basement membrane disease, systemic lupus
erythematosus nephritis, membranous glomerulonephritis
(MGN), and membranoproliferative glomerulonephritis. Of
these, the most common are aHUS and FSGS, the latter with a
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FIGURE 2 | Etiology of hypertension by time after transplant.
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observed for post-transplant hypertension in relation to time
after transplant.

univariate analysis. There was a noted trend of worsening hypertension with increasingly poor graft function on multivariate
analysis, but the study was underpowered to detect this effect
(67). A Finnish cohort found that only decreased diastolic dipping could predict lower GFR (68). More recently in a Greek
cohort, 20-year graft survival was superior for patients without
hypertension at 10 years follow-up after kidney transplant compared to those with hypertension (100 vs. 44.4%, P < 0.05) (14).
As well established in native kidneys with CKD, the presence of
poorly controlled hypertension also negatively affects renal graft
function over time.
A Dutch cohort study looking at long-term CVD outcomes
in kidney transplant recipients (with an average follow-up of
15. 5 years) who developed ESRD as children (0–14 years of
age) found that ~50% of males and 40% of females had LVH,
13% had diastolic dysfunction, and aortic valve calcification
was seen in 25% males and 12% female patients (69). Duration
of PD was independently associated with development of aortic
valve calcifications and diastolic dysfunction increased over time
and correlated with low GFR. This study also demonstrated an
era effect as patients who developed ESRD in the 1970s and
1980s had increased prevalence of CVD prior to more aggressive blood pressure control, ubiquitous use of erythropoietinstimulating agents, frequent avoidance of aluminum, and
limited use of calcium-based phosphorus binders (69). A similar
recent Dutch cohort still continued to show era effects in CVD
outcomes with improved management of hypertension and
hyperlipidemia (70).
In conclusion, children with CKD/ESRD come to transplant
with significant burden of hypertension and CVD. With transplantation, their CVD risk improves overall but may be negatively
impacted by poor control of blood pressure, by decline in GFR
overtime, and by the presence of hyperlipidemia, obesity, and
hyperglycemia.

EFFECT OF HYPERTENSION ON CVD
AND ALLOGRAFT FUNCTION
Definitive cardiovascular outcomes such as stroke, myocardial
infarction, and death are uncommon in the pediatric age
group. Pediatric studies have relied on the use of intermediate
endpoints such as LVH as measured by left ventricular mass
index (LVMI), carotid intima-media thickness (cIMT), and
pulse wave velocity (PWV) for CVD risk stratification. It has
been well described that pediatric patients with CKD and
ESRD have significantly increased cardiovascular morbidity
and mortality compared to their healthy peers (60, 61). CVD
accounts for approximately 30% of mortality among pediatric
kidney transplant recipients (9).
Long-standing hypertension has been shown to result in LVH
and increased LVMI and cIMT, all known risk factors for CVD
(2). LVH is prevalent in approximately 50% of patients with CKD
and ESRD and in kidney transplant recipients. A single-center
study comparing pretransplant echocardiography (ECHO) with
posttransplant ECHO showed that interval decrease in indexed
SBP was the only predictor of LVMI improvement on multivariate
analysis (62). A cross-sectional study in 2004 found that children
with a kidney transplant were more likely to have elevated LVMI
and diastolic dysfunction than healthy controls (63). However,
another study found no difference in systolic or diastolic function between normotensive and hypertensive pediatric transplant
recipients using the same tissue Doppler technique (2).
Evidence suggests that hypertension itself, regardless of BP
level, is associated with LVH. Specifically, Hamdani et al. showed
that treated hypertensive individuals with a normal blood pressure
had a greater prevalence of LVH than normotensive individuals
not treated with antihypertensive medications. In this same study,
a large pediatric cohort of 221 patients evaluated with ambulatory
blood pressure monitoring (ABPM), it was noted that patients
with normal blood pressure who did not require antihypertensive
medications had less allograft dysfunction than patients taking
antihypertensive medications and even in those whose BP was
in normal range (64). This emphasizes the point that children
with pharmacologically controlled hypertension are still at an
increased CVD risk compared to normotensive individuals
and require close screening for intermediate risk factors and
endpoints.
Masked hypertension as determined by ABPM in both
patients receiving and not receiving antihypertensive therapy
has an estimated prevalence of 25–35% (65). While smaller studies have not been able to find an association between masked
hypertension and graft function, a recent study by Hamdani
et al. showed that pediatric transplant recipients with masked
hypertension had significantly worse graft function than their
normotensive peers (66).
A study aimed at assessing CVD risk factors in pediatric
transplant patients found that there was a negative correlation
between GFR and SBP ± diastolic blood pressure (DBP) on
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BLOOD PRESSURE MEASUREMENT AND
ASSESSMENT OF CVD RISK
Screening for hypertension can be achieved by several methods
that include casual clinic blood pressure measurement, home and
school blood pressure measurement, and 24-h ABPM. ABPM
has been shown to be the most reliable method for measuring
blood pressure. It also has the added benefit of determining BP
load and predicting LVH (71–73). Pediatric patients with ESRD
who lack nocturnal dipping as characterized by a decrease of
>10% in nighttime blood pressure compared to daytime blood
pressure are deemed to be at an increased risk of LVH. However,
this was not borne out in another recent study that showed that
hypertensive children without ESRD who have nocturnal nondipping have similar prevalence of LVH compared to hypertensive children without non-dipping (74, 75).
Before widespread use of ABPM, we must recognize its current limitations. Primarily, controversy remains about how to
best interpret ABPM results due to lack of diverse normative data.
Currently available normative data are based on ABPM measurements of 949 healthy children published by the German Working
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Myocardial Strain Analysis

Group of Pediatric Hypertension (76). All children included in
this study were of European descent, relatively few short children
(<140 cm) were included, and there was a lack of variability in
DBPs within the group raising question about the algorithm used
to calculate the normal values.

The majority of coronary artery disease in CKD patients is
asymptomatic and may initially present with arrhythmia and
sudden death. Assessing the degree of myocardial strain using
ECHO or magnetic resonance (MR) imaging can detect more
subtle changes of impaired cardiovascular function, thus offering
an opportunity for early intervention.
Echocardiographic strain imaging helps to objectively quantify myocardial function (91). An extension of this is global
longitudinal strain (GLS) analysis, which can be used to detect
subtle changes in left ventricular function. GLS has been shown
to be independently associated with all-cause and CV mortality
in adult patients with CKD and after renal transplant. It is a
more reliable marker than ejection fraction for mortality (92,
93). Pirat et al. demonstrated that ESRD patients with a normal
ejection fraction had signs of subclinical myocardial disease
as determined by impaired longitudinal, circumferential, and
radial strain as well as strain rate (94). In that same study,
patients who underwent renal transplantation had improvement in all of these parameters compared to the patients receiving chronic dialysis. The clinical characteristics that negatively
affect GLS and basal longitudinal systolic strain were shown to
include increased interventricular septal thickness, diabetes,
low ejection fraction, increased DBP, and regular dialysis (95).
This again highlights the role of hypertension as a modifiable
risk factor.
Cardiac MR is a relatively newer imaging modality that can
provide additional information about CV risks in the CKD
population. Blood oxygen level-dependent cardiac MR can be
used to assess myocardial tissue oxygenation. A recent study
employing this technique found that patients with CKD and renal
transplant without known coronary artery disease had impaired
myocardial response to stress, independent of the presence of
diabetes mellitus, LVH, and myocardial scar (96). An additional
use for cardiac MR imaging is to estimate LVM, which has been
shown to closely correlate with autopsy findings of heart size.
A recent study compared ECHO and cardiac MR in their ability
to measure LVM in hypertensive pediatric patients and found
that ECHO generally overestimated the presence of LVM and
cardiac MR was a much more reliable method (97).
As these technologies become more readily available and costeffective in clinical practice, they will be able to offer more reliable
tools to assess cardiovascular dysfunction in pediatric transplant
recipients.

Carotid Intimal Media Thickness

High-resolution ultrasonography provides a non-invasive
method for measuring cIMT. Increased cIMT, a marker for the
development and progression of vascular calcification, has been
documented in children as young as 8 years and correlates with
duration of CKD, time on dialysis, hyperhomocysteinemia, and
increased calcium–phosphorus product (77, 78). A recent metaanalysis showed that pediatric solid organ transplant recipients
have increased cIMT compared to healthy controls (79). Increased
cIMT has been shown to be a strong risk factor for myocardial
infarction and stroke in adults (80). Childhood hypertension has
been shown to predict increased adult cIMT by the Childhood
Cardiovascular Cohort (i3C) (81).
Hypertension has been shown to have a linear correlation with
cIMT in adults (82). Balzano et al. showed that although renal
transplant recipients had increased cIMT and LVMI compared
to healthy controls, there was no progression or worsening in
those who underwent annual ABPM monitoring and had wellcontrolled hypertension (83). This study is reassuring of the fact
that while renal transplant recipients have greater cIMT and
LVH than healthy controls, regular blood pressure monitoring
and aggressive blood pressure control can halt the progression of
these intermediate CVD outcomes.

Pulse Wave Velocity

Arterial PWV is a sensitive marker of arterial stiffness, which
makes it a good surrogate endpoint for CVD (84). Increased
arterial stiffness is an independent predictor of survival in the
general population and in CKD patients (85). Normative pediatric reference values are available based on a study of 1,000 healthy
children, which enabled the calculation of age- and heightspecific SD scores (86). This study was performed on patients
in Hungary, Italy, and Algeria with ages ranging between 6 and
20 years. Multiple regression analysis showed that age, height, and
blood pressure were major predictors of PWV.
Chronic kidney disease patients have been shown to have
increased PWV. The recent 4C Study looked at numerous cardiovascular endpoints including PWV and found that 20.1% of CKD
patients in their cohort had elevated PWV. In their analysis, the
rise in PWV was independent of eGFR and moderately correlated
with cIMT (87). Sinha et al. (2015) showed that in children with
advanced CKD, only poorly controlled hypertension but not GFR
was associated with a change in arterial stiffness when compared
to healthy matched controls (88). In addition, the Young Finn
study showed that childhood hypertension was related to higher
adult PWV (89). In pediatric kidney transplant recipients, PWV
has been shown to be increased compared to control patients
matched for age and weight/height (26, 90). Since pediatric
kidney transplant recipients have ongoing CKD, strict BP control
may help to lower PWV and future cardiovascular risk in this
population.

Frontiers in Pediatrics | www.frontiersin.org

MANAGEMENT OF HYPERTENSION
Acute Postoperative Management

There are no published guidelines or recommendations for the
immediate postoperative management of kidney transplant
recipients. We will describe our center’s practice based on our
clinical experience in this section. In the immediate postoperative
period (first week), the most likely etiology of hypertension is
fluid overload, side effect of high-dose steroid therapy for induction, and native kidney disease. In the first few postoperative
days, permissive hypertension is tolerated to ensure adequate
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graft perfusion especially in small children. Size discrepancy
of the donor and recipient arteries and relatively lower blood
pressure in the child can compromise early graft perfusion and
predisposition to thrombus formation. This necessitates higher
patient blood pressures and may require vasopressor support to
achieve this.
After a few days postoperatively, excess fluid begins to
mobilize and move into the intravascular space, contributing to
hypertension. Allowing gradual diuresis back to the patient’s dry
weight will often result in decrease of the systemic blood pressure.
However, patients frequently need to be restarted or initiated on
antihypertensive medications during the postoperative period.

the need to maintain adequate hydration; however, a thiazide
diuretic may be effective in helping control CNI-mediated
hypertension due to its action through the thiazide-sensitive
Na-Cl channel (30, 107).

Dietary Counseling

While pharmacological interventions have an important role in
the management of hypertension, dietary and exercise counseling
need to be at the forefront of long-term management of transplant
recipients.
Diets high in sodium and low in potassium have been shown
to aggravate hypertension. In a Belgian study of adult patients,
dietary history and urinary sodium and potassium excretion
were evaluated. While sodium intake did not differ between the
two groups (~10 g/day), patients with controlled blood pressure
consumed higher amounts of potassium by regularly eating
more fruits and vegetables, which lowered their observed Na+/
K+ ratio (108). Asai et al. demonstrated that repeated dietary
counseling resulted in a statistically significant reduction in mean
24-h urinary sodium excretion and SBP (109). Similarly, de Vries
et al. also showed that dietary sodium restriction in adult kidney
transplant recipients resulted in statistically significant reductions
in SBP and DBP (110). Both of these studies had small sample
size, and therefore, it is impressive that the noted changes in blood
pressure were able to reach statistical significance.
In accordance with these findings, published nutritional
guidelines for renal transplant recipients include low-sodium
diet and weight loss in obese individuals to optimize blood pressure management (111). Counseling of patients should be done
routinely, as infrequent counseling has been shown to be not
effective (112).

Long-term Management

A holistic approach to the long-term management of hypertension should be pursued in the pediatric transplant recipient. As
the goal of hypertensive management is ultimately to prolong
patient and graft survival and decrease CVD, this approach
should include close monitoring and management of graft
function as well as adherence to medications, diet, and exercise.
Many review papers have been published on the pharmacologic
management of hypertension (1, 98, 99). The current KDIGO
position is that no class of antihypertensive medications is
contraindicated in transplant recipients (100). In clinical practice, calcium channel blockers (CCBs) and ACE-I are the most
common first-line medications (101–103). While permissive
hypertension is tolerated immediately after transplant surgery,
the ultimate goal of therapy should be to target normal blood
pressures (<90th percentile) and try to achieve control near the
50th percentile for age.
As with hypertension in patients without renal transplant,
pharmacologic therapy should be aimed at addressing the
underlying etiology. In patients on CNI-based immunosuppression, afferent arteriole vasoconstriction contributes to
hypertension, and therefore, a use of CCBs is usually the
first-line therapy due to its vasodilatory properties. CCBs
have a very good safety profile and have been shown to be
efficacious in this patient population for both blood pressure
control and improvement of GFR compared to placebo treated
patients (101). In non-transplant patients, the benefit of ACE-I
in the pediatric CKD population with proteinuria has been
well described (51). Less concrete evidence exists for the use of
ACE-I in kidney transplant recipients. Knoll et al. performed a
multicenter double-blind placebo-controlled study comparing
ramipril to placebo and found no benefit in allograft survival
in the treatment group. His study was underpowered to detect
a difference and may account for their null results (104). A
recent meta-analysis to look at the effects of ACE-I on graft
survival also found no benefit (105). A small case series in a
pediatric population found that ACE-I appeared to stabilize
creatinine in patients with chronic allograft dysfunction, but
statistical analysis could not support the renoprotective effect
of ACE-I on long-term graft survival (106). Meta-analysis
by Cross et al. showed that therapy with ACE-I can reduce
proteinuria, however there are not enough data to support
that this improves graft survival (101). Diuretics are not usually employed in the pediatric transplant population due to

Frontiers in Pediatrics | www.frontiersin.org

Systems-Based Approach

Changes and improvement in management of hypertension in
the pediatric kidney transplant population can be approached
using quality improvement methodology. Because this is a
complex multifaceted problem that affects patients’ long-term
outcomes and requires multidisciplinary cooperation, this can
be addressed by employing the Chronic Care Model as suggested
by Hooper and Mitsnefes (113). Recommendations include
implementation of clinic visit checklists to ensure that blood
pressure, diet, and lifestyle risk factors are addressed regularly
at every clinic visit, augmenting the electronic health record
(EHR) to calculate blood pressure percentiles, pop-up reminders for annual ABPM screening, and employing novel technology to encourage activity and participation among transplant
recipients.

CONCLUSION
Hypertension in the pediatric kidney transplant recipients is
highly prevalent and often underrecognized and undertreated.
This contributes to worse allograft function and long-term risk of
CVD in early adulthood and partly accounts for the significantly
increased mortality in this patient population. Hypertension is a
modifiable risk factor that should be aggressively monitored and
treated, as summarized in Figure 3. Annual 24-h ABPM and
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a combination of pharmacological and lifestyle interventions
to optimize care utilizing a multidisciplinary team. Currently,
quality improvement methodology and EHR technology provide
an opportunity to customize workflows and build in templates/
reminders to optimize patient care and improve patient outcomes.

Key Points
•

Prevalence is very high

•
•

Multifactorial etiology
Frequently under recognized
and undertreated

•

Significant contributor to
long-term morbidity and
mortality

•

Controlled hypertension helps
to preserve allograft function
and decrease cardiovascular
morbidity and mortality

FUTURE RESEARCH
There are many gaps in our knowledge in this field that would
benefit from further research including but not limited to CVD
outcomes based on the donor KDPI; genetic polymorphism of
donors affecting posttransplant hypertension in transplant recipients; ABPM normative data of diverse ethnic populations; blood
pressure percentile treatment goals for transplant recipients;
effect of ACE-I on long-term graft survival, and finally, addressing barriers to adherence at both provider and patient level with
adequate treatment plan.

FIGURE 3 | Key points.
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